to-BBB Further Strengthens Supervisory Board with Dr. Peter Høngaard Andersen
to-BBB announced the addition of Dr. Peter Høngaard Andersen to its Supervisory Board. Dr. Andersen brings many years of pharma drug development experience to the Board. His experience and strategic guidance will be instrumental to further build to-BBB as a leading company in brain drug development.
Dr. Peter Høngaard Andersen is currently the Sr. VP Global Public Affairs and Corporate Patents & Trademarks at Lundbeck, the Danish global pharma company focused on brain diseases. He previously held multiple senior R&D positions for Lundbeck and Novo Nordisk. Dr. Andersen holds degrees in chemistry, biochemistry and medicine from University of Copenhagen. He currently holds Board seats at Epitherapeutics and at Prexton Therapeutics, as well as board positions for the European pharmaceutical industry (EFPIA and IMI).
Other news from the department people
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.